The U.S. Food and Drug Administration on Friday approved alirocumab, the first of a new class of injected, cholesterol-lowering drugs.
Alirocumab cuts levels of LDL cholesterol, and is one of a group of newly developed drugs called PCSK9 inhibitors. The molecule happens to be a monoclonal antibody.
Approved indications
- The drug is only approved for patients with heart disease and a history of heart attack or stroke "who require additional lowering of LDL cholesterol" in addition to taking a statin drug and adopting a healthy diet.
- Heterozygous familial hypercholesterolemia (HeFH), an inherited illness that causes people to have high levels of LDL in the blood.
>
Comments
Post a Comment